Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Careers
Investors
News
Contact
Advancing the Use of Peptide-Conjugated Oligonucleotides to Target Neuromuscular Disorders: Enhanced Delivery Oligonucleotides for DMD and DM1
Post navigation
Previous:
FREEDOM-DM1: Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 for Myotonic Dystrophy Type 1
Next:
Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 Clinical Trials in Myotonic Dystrophy Type 1
